GlassScriptPhysician profile
Raquel B Empedrad
NPI 1902896988
$21,059.26
in general payments reported to CMS, 2019-2025
39 companies · $5,452 in 2025
The $5,452 reported for 2025 was more than what 84% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,448 · 2020: $1,456 · 2021: $2,048 · 2022: $3,002 · 2023: $3,863 · 2024: $3,790 · 2025: $5,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,854.10 |
| Education | $251.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,775.75 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $3,524.60 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $2,466.41 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,119.25 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,073.27 | 2019-2025 | Dupixent |
| Pfizer INC. | $949.81 | 2019-2025 | |
| Incyte Corporation | $914.84 | 2021-2025 | Opzelura, Opzelura |
| Amgen INC. | $618.39 | 2021-2025 | Tezspire |
| Optinose US, INC. | $599.47 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $551.49 | 2020-2025 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $516.39 | 2019-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $492.88 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.03 | 2019-2024 | Spiriva Respimat |
| Abbvie INC. | $379.60 | 2022-2025 | |
| Csl Behring | $350.66 | 2019-2025 | Haegarda, Andembry |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $305.54 | 2025 | Neffy |
| Kaleo, INC. | $299.08 | 2019-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $294.50 | 2021-2025 | Orladeyo |
| Galderma Laboratories, L.P. | $161.61 | 2024-2025 | Nemluvio |
| Grifols USA, LLC | $158.90 | 2020-2025 | Xembify |
| Sanofi-Aventis U.S. LLC | $154.98 | 2025 | |
| Covis Pharma Gmbh | $143.63 | 2021-2022 | |
| Alk-Abello, INC | $111.65 | 2019-2023 | Ragwitek, Grastek, Odactra |
| Organon LLC | $99.37 | 2025 | Vtama |
| Lilly USA, LLC | $78.30 | 2024-2025 | Ebglyss |
| Philips North America LLC | $66.78 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $57.89 | 2020-2022 | |
| Ionis Pharmaceuticals, INC. | $56.33 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $52.86 | 2021-2025 | Ruconest |
| Mylan Specialty L.P. | $49.87 | 2020-2022 | |
| Octapharma USA, INC. | $38.52 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $34.32 | 2023 | |
| Hikma Pharmaceuticals USA | $29.08 | 2023-2024 | Ryaltris |
| Shire North American Group INC | $28.29 | 2019 | |
| Leo Pharma INC. | $26.92 | 2022 | |
| Blueprint Medicines Corporation | $20.49 | 2024 | Ayvakit |
| Phadia US INC. | $18.53 | 2024 | Immunocap |
| Paratek Pharmaceuticals, INC. | $17.98 | 2025 | Xhance |
| Cycle Pharmaceuticals INC | $17.00 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raquel Empedrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.